As CEO, Mr. Gregg is responsible for managing operations for AmbioPharm and serves on the Board of Directors. Prior to AmbioPharm, he had long and successful career at Bachem, a company specializing in the development and manufacture of peptides and oligonucleotides, where he held for 8 years the position of COO for Bachem Americas. In his extensive career at Bachem, Mr. Gregg has held a variety of positions in peptide manufacturing, quality and compliance, and operations management. His skills include driving business and operational growth and strategic acquisition and integration. He holds a MBA from San Diego State University and a BA in Chemistry from the University of California, San Diego.

Mr. Kiel is the Chief Financial Officer of Ambio Pharmaceuticals, the parent company of AmbioPharm. He is also Secretary/Treasurer of the Company and member of the Board since its formation in 2014. He is also primarily responsible for all capital markets activity.
As CFO, Mr. Kiel is responsible for the financial health of the organization, including accounting, financial reporting, cash management, and relations with investors, banks and government. He actively participates in negotiations and contract review,
He was previously a Partner at Deloitte Consulting, one of the nation’s Big Four accounting firms. He holds an MBA from The Ohio State University and was awarded a CPA (now inactive) and Series 7 license.

As Executive Vice President of Sales, Mr. Hutchings is responsible for the Sales and Marketing leadership globally for AmbioPharm. With over 30 years of experience in the Life Science and CDMO industry, he is a client focused professional, striving to develop strong client partnerships to improve human health by providing CMC solutions and supplying high quality APIs to the Pharma and Biotech communities from preclinical through to commercialization.
Prior to Ambiopharm, Mr. Hutchings held various Business Development leadership roles, both in Europe and the US, in companies including Packard Bioscience, RTS LifeSciences (now Azenta), PerkinElmer, Silicon Biosystems and more recently at Bachem Americas as VP of Business Development and Sales and VP, Head of Global Exclusive APIs.

As Vice President of Global Research and Development, Mr. Zhang is responsible for AmbioPharm’s process development activities at the North Augusta headquarters as well as the Shanghai site. He has more than 20 years’ experience in small- and large-scale peptide synthesis and manufacturing under current Good Manufacturing Practice. Mr. Zhang has expertise with SPPS, LPPS, and hybrid synthesis, successfully employing these approaches for the development of efficient, large-volume commercial peptide manufacturing processes. Additionally, Mr. Zhang establishes synthesis procedures for key building blocks including unnatural amino acids which are not commercially available for inclusion in the manufacture of API peptides. Prior to AmbioPharm, Mr. Zhang spent time at CPC Scientific.

As VP of Manufacturing, Mr. Patel is responsible for the day to day operations and long-term outlook of manufacturing at Ambiopharm, North Augusta. He has worked as a Senior Director, Production for 19+ years at Bachem, Torrance California followed by over 9 years as Senior Management in Manufacturing at Polypeptide Group in Torrance, California. He has managed API projects from Development to Commercial scale through the product life-cycle, including various regulatory approvals (i.e. FDA, PMDA, EMA), successfully bringing APIs to commercial (Multi-Kilo) scale. He holds a Master of Science degree in Organic Chemistry from SP University, India.

As Senior Vice President of Quality Assurance, Brant Zell leads the Quality Assurance organization at AmbioPharm globally. Mr. Zell has over 40 years of Quality and Compliance experience with over 13 years in the peptide API industry. He has dedicated his career in ensuring patient safety and health through setting and demanding appropriate current Good Manufacturing Practice. Prior to AmbioPharm, Mr. Zell oversaw Quality at PolyPeptide Laboratories. Mr. Zell is the one of the founders and chair of the Bulk Pharmaceutical Task Force, a group working directly with FDA leadership and representing the industry view on compliance, GDUFA, best practices, and regulatory concerns. Mr. Zell has a Master of Science in Analytical Chemistry and a Master of Business Administration and Technology Management.

As Vice President of Quality Control, Dr. Ye is responsible for quality control, method development and validation, and peptide characterization in AmbioPharm globally.
He has over 20 years of experience in the pharmaceutical, biopharmaceutical, and CDMO industry. His expertise is in quality control, analytical development/validation, analytical CMC strategy for small molecules, large molecules, and peptides/oligonucleotides.
Prior to AmbioPharm, Dr. Ye held various leadership roles in quality control and analytical development globally for companies including Bachem, WuXi AppTec, Ajinomoto Biopharma Services, Allergan, Merck KGaA, etc. He holds a Ph.D. in Analytical Chemistry from University of Calgary, Canada.

Mr. Gary Hu is Senior Vice President of Sales, responsible for sales and business development in Asia including India. Mr. Hu has more than 30 years of experience in the peptide, oligo, and small molecule CDMO industry. Prior to AmbioPharm, he held various leadership roles in business development, strategic alliances, licensing, sales, marketing, project management, and logistics at American Peptide Company and Bachem. In 2018, Mr. Hu established the Bachem K.K. entity in the pharma cluster of Nihonbashi in Tokyo Japan. He also served as board member of American Peptide Company and Bachem Japan K.K.

Sammi Liu possesses extensive work experience in various finance and HR roles. She joined AmbioPharm in 2013 and progressed from the role of Director of Corporate Finance and Investor Relations to her current position as VP of Finance and HR. Throughout her tenure, she supported the fundraising efforts for series A-1, series A-2, and series B rounds. Currently, she oversees the HR and Finance teams at both North Augusta headquarters and the Shanghai site.
Prior to joining AmbioPharm, Ms. Liu worked as a Marketing Specialist at Hang Lung Properties in Shanghai. She holds a Master of Philosophy from Shangdong University, an MBA specialized in Finance from Louisiana State University, and a certificate in Business Analytics from Harvard University.